2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
138
Breast Neoplasms
95
Neoplasms
8
Neoplasm Metastasis
6
Breast Neoplasms, Male
6
Advanced Breast Cancer
4
Salivary Gland Neoplasms
3
Prostate Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Osteoporosis
2
Leiomyoma
2
Infertility
2
Advanced Prostate Cancer
2
Stage I Prostate Adenocarcinoma AJCC v7
1
Sexual Dysfunctions, Psychological
1
Sexual Dysfunction, Physiological
1
Sarcopenia
1
Radiation Injuries
1
Primary Ovarian Insufficiency
1
Primary Dysautonomias
1
Patients With T1-4 Advanced Prostate Cancer
1
Patient Compliance
1
PSA Level Greater Than Two
1
Ovarian Neoplasms
1
Osteitis Deformans
1
Myofibroma
1
Lymphatic Metastasis
1
Kidney Diseases
1
Inflammatory Breast Neoplasms
1
Interventions
Fulvestrant
10
Alpelisib
7
Everolimus
6
Cetuximab
6
Letrozole
4
serabelisib
3
ribociclib
3
pembrolizumab
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
NVP-BKM120
3
Irinotecan
3
sapanisertib
2
parsaclisib
2
olaparib
2
binimetinib
2
Topotecan
2
Gemcitabine
2
Carboplatin
2
volagidemab
1
venetoclax
1
tivozanib
1
tipifarnib
1
tanezumab
1
talazoparib
1
sotorasib
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Goserelin
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts